Membrane vesicles for nanoencapsulated sulforaphane increased their anti-inflammatory role on an In vitro human macrophage model.

Abstract

At present, there is a growing interest in finding new non‐toxic anti‐inflammatory drugs to treat inflammation, which is a key pathology in the development of several diseases with considerable mortality. Sulforaphane (SFN), a bioactive compound derived from Brassica plants, was shown to be promising due to its anti‐inflammatory properties and great potential, though its actual clinical use is limited due to its poor stability and bioavailability. In this sense, the use of nanocarriers could solve stability‐related problems. In the current study, sulforaphane loaded into membrane vesicles derived from broccoli plants was studied to determine the anti‐inflammatory potential in a human‐macrophage‐like in vitro cell model under both normal and inflammatory conditions. On the one hand, the release of SFN from membrane vesicles was modeled in vitro, and two release phases were stabilized, one faster and the other slower due to the interaction between SFN and membrane proteins, such as aquaporins. Furthermore, the anti‐inflammatory action of sulforaphane‐loaded membrane vesicles was demonstrated, as a decrease in interleukins crucial for the development of inflammation, such as TNF‐α, IL‐1β and IL‐6, was observed. Furthermore, these results also showed that membrane vesicles by themselves had anti‐inflammatory properties, opening the possibility of new lines of research to study these vesicles, not only as carriers but also as active compounds.